Outlook therapeutics® announces acceptance of biologics license application by u.s. fda for ons-5010 as a treatment for wet amd

Prescription drug user fee act (pdufa) goal date of august 27, 2025 iselin, n.j., april 08, 2025 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company that achieved regulatory approval in the european union (eu) and the united kingdom (uk) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet amd), today announced that the u.s. food and drug administration (fda) has acknowledged receipt of the resubmission of the biologics license application (bla) for ons-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet amd.
AMD Ratings Summary
AMD Quant Ranking